… been the first series of anti-EGFR selective agents tested.[4–9] … anti-EGFR blocking MAb, is
the first agent that specifically … selective EGFR-TKIs suitable for use as anticancer agents has …

… The epidermal growth factor receptor (EGFR) plays a crucial role in cell … , EGFR kinases
are promising targets for cancer therapy. Many of the existing EGFR inhibiting anticancer agents …

… EGFR family kinase inhibitors are a class of important agents centered on blocking EGFR …
ing EGFR family mainly result in the suppression of EGFR, HER2 and HER4. Up to date, six …

… The anti-epidermal-growth-factor-receptor (EGFR) monoclonal antibody cetuximab specifically
binds to the EGFR with high affinity, blocking growth-factor binding, receptor activation …

… different anticancer agents, class by class, in association with EGFR … chemosensitization by
EGFR blocking using mAbs, … the antitumor activity of several anticancer agents (doxorubicin, …

… , treatment with EGFR kinase inhibitors (or EGFR-blocking antibodies) as single agents results
in … This was predicted based on the performance of EGFR-inhibiting agents in preclinical …

… trans-phosphorylation, thereby blocking the signalling pathway. … EGFR) signalling pathways
currently being investigated as part of the development of potential new anticancer agents…

… Numerous EGFR blockers have been investigated, and some of these are now being used
… developed for EGFR and HER2, these only appear to be effective as anticancer agents in a …

… the EGFR and to demonstrate that blockade of this receptor might represent a promising
anti-cancer … Treatment with blocking monoclonal antibodies directed against the EGFR usually …

… The challenges we face in the design and interpretation of clinical trials of MEK inhibitors
do not differ substantially from those faced with other anticancer agents, particularly signal-…